JP2018108997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018108997A5 JP2018108997A5 JP2018001678A JP2018001678A JP2018108997A5 JP 2018108997 A5 JP2018108997 A5 JP 2018108997A5 JP 2018001678 A JP2018001678 A JP 2018001678A JP 2018001678 A JP2018001678 A JP 2018001678A JP 2018108997 A5 JP2018108997 A5 JP 2018108997A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- chloro
- pharmaceutically acceptable
- prodrug
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino, hydroxyl Chemical group 0.000 claims description 175
- 150000003839 salts Chemical class 0.000 claims description 92
- 239000000651 prodrug Substances 0.000 claims description 88
- 229940002612 prodrug Drugs 0.000 claims description 88
- 150000001875 compounds Chemical class 0.000 claims description 86
- 239000001257 hydrogen Substances 0.000 claims description 56
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical group 0.000 claims description 33
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 30
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 125000004429 atom Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 7
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 4
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 3
- LLAPDLPYIYKTGQ-UHFFFAOYSA-N 1-aminoethyl Chemical group C[CH]N LLAPDLPYIYKTGQ-UHFFFAOYSA-N 0.000 claims description 2
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 claims description 2
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 claims description 2
- 230000000626 neurodegenerative effect Effects 0.000 claims description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- QRAOZQGIUIDZQZ-UHFFFAOYSA-N 4-methyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1,4-benzoxazine Chemical compound C=1C=C2N(C)CCOC2=CC=1B1OC(C)(C)C(C)(C)O1 QRAOZQGIUIDZQZ-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- INFKWNUZDNIJDQ-KYDCKOQZSA-N CC(Cc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)COc1c2Cl Chemical compound CC(Cc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)COc1c2Cl INFKWNUZDNIJDQ-KYDCKOQZSA-N 0.000 description 1
- BPQDTVIIWUGOJZ-VJCKSVEBSA-N CC(Cc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)Oc1c2Cl Chemical compound CC(Cc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)Oc1c2Cl BPQDTVIIWUGOJZ-VJCKSVEBSA-N 0.000 description 1
- KSIQRBJGSITOLR-TWELXNIESA-N CC(Oc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)Oc1c2Cl Chemical compound CC(Oc1cc(C([C@@H](C2)[C@H]2C(O)=O)=O)c2)Oc1c2Cl KSIQRBJGSITOLR-TWELXNIESA-N 0.000 description 1
- CMTXOMMPDQBUPO-YUMQZZPRSA-N OC([C@@H](C1)[C@H]1C(c1cc(Cl)c2OCCOc2c1)=O)=O Chemical compound OC([C@@H](C1)[C@H]1C(c1cc(Cl)c2OCCOc2c1)=O)=O CMTXOMMPDQBUPO-YUMQZZPRSA-N 0.000 description 1
- JWUSMOIXSPWZAO-BQBZGAKWSA-N OC([C@@H](C1)[C@H]1C(c1cc(Cl)c2OCOc2c1)=O)=O Chemical compound OC([C@@H](C1)[C@H]1C(c1cc(Cl)c2OCOc2c1)=O)=O JWUSMOIXSPWZAO-BQBZGAKWSA-N 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620953P | 2012-04-05 | 2012-04-05 | |
| US61/620,953 | 2012-04-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504581A Division JP6275690B2 (ja) | 2012-04-05 | 2013-03-13 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018108997A JP2018108997A (ja) | 2018-07-12 |
| JP2018108997A5 true JP2018108997A5 (enExample) | 2018-12-20 |
| JP6622824B2 JP6622824B2 (ja) | 2019-12-18 |
Family
ID=49300915
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504581A Active JP6275690B2 (ja) | 2012-04-05 | 2013-03-13 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
| JP2018001678A Active JP6622824B2 (ja) | 2012-04-05 | 2018-01-10 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504581A Active JP6275690B2 (ja) | 2012-04-05 | 2013-03-13 | キヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9822058B2 (enExample) |
| EP (2) | EP2833879A4 (enExample) |
| JP (2) | JP6275690B2 (enExample) |
| KR (1) | KR20150000882A (enExample) |
| CN (1) | CN104244939A (enExample) |
| AR (1) | AR090601A1 (enExample) |
| AU (1) | AU2013243898A1 (enExample) |
| BR (1) | BR112014024693A2 (enExample) |
| CA (1) | CA2868321A1 (enExample) |
| EA (1) | EA201491606A1 (enExample) |
| ES (1) | ES2972419T3 (enExample) |
| HK (1) | HK1206264A1 (enExample) |
| IL (1) | IL234884A0 (enExample) |
| MX (1) | MX2014011946A (enExample) |
| PH (1) | PH12014502218A1 (enExample) |
| SG (1) | SG11201406311UA (enExample) |
| TW (1) | TW201402537A (enExample) |
| WO (1) | WO2013151707A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140072037A (ko) | 2011-08-30 | 2014-06-12 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법 |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| KR20150000882A (ko) * | 2012-04-05 | 2015-01-05 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법 |
| EP3049077A4 (en) * | 2013-09-26 | 2017-02-15 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| ES2754473T3 (es) | 2013-09-26 | 2020-04-17 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas, y método de uso de los mismos |
| GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| AU2015289492B2 (en) | 2014-07-17 | 2020-02-20 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| WO2016027757A1 (ja) * | 2014-08-18 | 2016-02-25 | 国立大学法人大阪大学 | 新規２－アミノベンゾイル誘導体 |
| GB201507753D0 (en) * | 2015-05-06 | 2015-06-17 | Biolipox Ab | New compounds and uses |
| MX378983B (es) * | 2015-05-07 | 2025-03-10 | Chdi Foundation Inc | Inhibidores de histona deacetilasa y composiciones y metodos para el uso de los mismos. |
| AU2016256917B2 (en) * | 2015-05-07 | 2021-08-26 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| GB201508857D0 (en) * | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
| GB201508864D0 (en) * | 2015-05-22 | 2015-07-01 | Glaxosmithkline Ip Dev Ltd | Compounds |
| JP7623784B2 (ja) | 2016-10-13 | 2025-01-29 | ジュノー セラピューティクス インコーポレイテッド | トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物 |
| US11911376B2 (en) | 2020-03-30 | 2024-02-27 | The Regents Of The University Of Colorado | Methods for preventing and treating retinal damage |
| US20240043372A1 (en) * | 2020-10-06 | 2024-02-08 | Pharmaceutique Ingenew Inc. | Substituted aromatic compounds and pharmaceutical compositions thereof |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN113816887A (zh) * | 2021-08-31 | 2021-12-21 | 华中科技大学 | 一种氮杂环丙烷类化合物及其制备方法 |
| CN119143707B (zh) * | 2024-11-20 | 2025-01-28 | 山东第一医科大学(山东省医学科学院) | 一种螺旋-2(3h)-呋喃酮分子及其制备方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US228550A (en) * | 1880-06-08 | Peters | ||
| DE3124699A1 (de) | 1981-06-24 | 1983-01-13 | Basf Ag, 6700 Ludwigshafen | Neue 2-aryl-3,4-diaza-bicyclo(4.n.0.)alken-(2)-one-(5),verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3535170A1 (de) | 1985-10-02 | 1987-04-16 | Basf Ag | Verwendung von 2-aryl-3,4-diaza-bicyclo(4.n.0)alken-(2)-onen-(5) zur behandlung der herzinsuffizienz |
| GB8712466D0 (en) | 1987-05-27 | 1987-07-01 | Roussel Lab Ltd | Chemical compounds |
| GB8908846D0 (en) | 1989-04-19 | 1989-06-07 | Roussel Lab Ltd | Chemical compounds |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| GB9522617D0 (en) * | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| GB9522615D0 (en) | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| GB9705031D0 (en) * | 1997-03-11 | 1997-04-30 | Pharmacia & Upjohn Spa | 2-substituted benzoyl-cycloalkyl-1-carboxylic acid derivatives |
| GB9714303D0 (en) | 1997-07-07 | 1997-09-10 | Pharmacia & Upjohn Spa | 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives |
| DE19952147A1 (de) * | 1999-10-29 | 2001-05-03 | Boehringer Ingelheim Pharma | Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP2004531506A (ja) * | 2001-03-29 | 2004-10-14 | ブリストル−マイヤーズ スクイブ カンパニー | 選択的なセロトニン再取り込みインヒビターとしてのシクロプロピルインドール誘導体 |
| US20040077616A1 (en) * | 2002-10-22 | 2004-04-22 | Bennani Youssef L. | Spirocyclopropyl amides and acids and their therapeutic applications |
| EP1424333A1 (en) * | 2002-11-28 | 2004-06-02 | Newron Pharmaceuticals S.p.A. | Halothenoyl-cyclopropane-1-carboxylic acid derivatives |
| JP2006525347A (ja) | 2003-04-29 | 2006-11-09 | オシエント ファーマシューティカルズ | 抗生テトラヒドロ−β−カルボリン誘導体 |
| EP1475385A1 (en) * | 2003-05-05 | 2004-11-10 | Newron Pharmaceuticals S.p.A. | Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid |
| EP1692124B1 (en) | 2003-12-04 | 2008-10-15 | Wyeth | Biaryl sulfonamides as mmp inhibitors |
| ITMI20041626A1 (it) | 2004-08-06 | 2004-11-06 | Roberto Pellicciari | Inibitori della chinurenina-ammino-trasferasi |
| WO2006077901A1 (ja) | 2005-01-20 | 2006-07-27 | Shionogi & Co., Ltd. | Ctgf発現阻害剤 |
| WO2009034029A2 (de) * | 2007-09-07 | 2009-03-19 | Boehringer Ingelheim International Gmbh | 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten |
| PL2242749T3 (pl) | 2008-02-05 | 2013-09-30 | Hoffmann La Roche | Nowe pirydynony i pirydazynony |
| CA2715835C (en) * | 2008-02-29 | 2017-03-21 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| WO2010011302A1 (en) * | 2008-07-22 | 2010-01-28 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| KR20150000882A (ko) * | 2012-04-05 | 2015-01-05 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법 |
| ES2754473T3 (es) | 2013-09-26 | 2020-04-17 | Chdi Foundation Inc | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas, y método de uso de los mismos |
| EP3049077A4 (en) | 2013-09-26 | 2017-02-15 | CHDI Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
-
2013
- 2013-03-13 KR KR1020147027810A patent/KR20150000882A/ko not_active Withdrawn
- 2013-03-13 EP EP13772200.5A patent/EP2833879A4/en not_active Withdrawn
- 2013-03-13 EP EP16186005.1A patent/EP3130583B1/en active Active
- 2013-03-13 WO PCT/US2013/031051 patent/WO2013151707A1/en not_active Ceased
- 2013-03-13 MX MX2014011946A patent/MX2014011946A/es unknown
- 2013-03-13 CA CA2868321A patent/CA2868321A1/en not_active Abandoned
- 2013-03-13 US US14/390,190 patent/US9822058B2/en active Active
- 2013-03-13 BR BR112014024693A patent/BR112014024693A2/pt not_active IP Right Cessation
- 2013-03-13 HK HK15106937.6A patent/HK1206264A1/xx unknown
- 2013-03-13 CN CN201380018756.2A patent/CN104244939A/zh active Pending
- 2013-03-13 JP JP2015504581A patent/JP6275690B2/ja active Active
- 2013-03-13 ES ES16186005T patent/ES2972419T3/es active Active
- 2013-03-13 SG SG11201406311UA patent/SG11201406311UA/en unknown
- 2013-03-13 EA EA201491606A patent/EA201491606A1/ru unknown
- 2013-03-13 AU AU2013243898A patent/AU2013243898A1/en not_active Abandoned
- 2013-04-03 TW TW102112072A patent/TW201402537A/zh unknown
- 2013-04-04 AR ARP130101101A patent/AR090601A1/es unknown
-
2014
- 2014-09-29 IL IL234884A patent/IL234884A0/en unknown
- 2014-10-01 PH PH12014502218A patent/PH12014502218A1/en unknown
-
2017
- 2017-11-14 US US15/813,001 patent/US10442782B2/en active Active
-
2018
- 2018-01-10 JP JP2018001678A patent/JP6622824B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018108997A5 (enExample) | ||
| JP2017081918A5 (enExample) | ||
| JP2018534270A5 (enExample) | ||
| AU2016299485B2 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| RU2453532C2 (ru) | Аминосоединение и его фармацевтическое применение | |
| JP2020524719A5 (enExample) | ||
| JP2020033357A5 (enExample) | ||
| AU2014219283C1 (en) | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders | |
| JP2020504753A5 (enExample) | ||
| JP2020125349A (ja) | 医薬化合物 | |
| JP2023537632A5 (enExample) | ||
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| RU2013105490A (ru) | Спироциклические аминовые производные в качестве модуляторов s1p | |
| JP2011527686A5 (enExample) | ||
| RU2007137133A (ru) | Новый ингибитор hsp90 | |
| RU2007118632A (ru) | Ингибиторы митотического кинезина и способы их использования | |
| EA021126B1 (ru) | Замещенные изохинолиноны и хинализолиноны | |
| JP2013504544A5 (enExample) | ||
| JP2008535930A5 (enExample) | ||
| JP2007504241A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| RU2006109599A (ru) | Гетероциклические ингибиторы мек и способы их применения | |
| RU2012106743A (ru) | Производные хромонов, способ их получения и их терапевтические применения | |
| CA2810150C (en) | P2x4 receptor antagonist |